A 12-month extension to: a randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of once weekly alendronate and risedronate on bone mineral density in postmenopausal women with osteporosis.

Trial Profile

A 12-month extension to: a randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of once weekly alendronate and risedronate on bone mineral density in postmenopausal women with osteporosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Alendronic acid; Risedronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top